Key result
Metoprolol and methyldopa did not affect treadmill walking capacity compared to placebo in hypertensive patients with intermittent claudication.
Why the study?
Does a 3-week course of metoprolol and methyldopa affect walking capacity in hypertensive patients with intermittent claudication?
Population
14 hypertensive patients with intermittent claudication
Comparison
3-week course of treatment with metoprolol and… vs Placebo
Design
RCT, double-blind
Follow-up
3 weeks
Authors
Loading...
Supports short-term use without claudication concern; confirms neutral effect on walking capacity in this RCT.
Does a 3-week course of metoprolol and methyldopa affect walking capacity in hypertensive patients with intermittent claudication?
Short-term antihypertensive treatment with metoprolol and methyldopa does not significantly impair or improve treadmill walking capacity in patients with intermittent claudication.
Lepäntalo et al. (1984) studied this question. Metoprolol and methyldopa did not affect treadmill walking capacity compared to placebo in hypertensive patients with intermittent claudication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: